Annual General Meeting 2021

The virtual Annual General Meeting 2021 took place on Tuesday, April 13 at 2:00 PM CEST.

Annual General Meeting 2021

Watch the webcast replay

Please click on the links below for information concerning Genmab A/S’ Annual General Meeting 2021:

Shareholder letter
Notice of Annual General Meeting 2021 with agenda, including Appendix 1: Candidates for the Board of Directors and Appendix 2: Proposed amended Remuneration Policy
Registration to participate (deadline Friday April 9, 2021, at 11:59 PM CEST)
Proxy and postal vote form
Submit proxy or postal vote online
2020 Annual Report of Genmab A/S
2020 Compensation Report
Technical Requirements & Practical Information
Link to the AGM portal (only fully accessible upon registration)

The total number of voting rights and total share capital per March 9, 2021 are:
Total Number of Voting Rights: 65,587,322.
Total Share Capital: 65,587,322.

Technical assistance
Questions regarding registration to participate, attending the virtual Annual General Meeting as well as any technical related questions before or during the General Meeting may be directed to VP Securities A/S tel. no. (+45) 43 58 88 94 or [email protected].

We process your personal data in accordance with applicable rules. Please click here to read our Privacy Policy.

Please note that Genmab A/S, as a general rule, no longer sends the calling to Annual General Meetings by postal mail. If you wish to receive the invitation to future Annual General Meetings via e-mail, please register your e-mail address at the InvestorPortal. If you do not have access to an e-mail address, please contact VP Investor Services at: +45 4358 8866.

Investor inquiries

  • Who we are

    Read about Genmab’s purpose, core values and key accomplishments

    Learn more

  • Turning insights into medicine

    See the results of innovation that is rooted in science

    Explore the pipeline

  • Innovation for the future

    We are developing next-generation technologies

    See our technologies

You are now leaving to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.